Nexalin Technology (NXL) Capital Expenditures (2026)
Nexalin Technology (NXL) recorded quarterly Capital Expenditures of $49276.0 in Q1 2026.
Nexalin Technology (NXL) Capital Expenditures (2026) Analysis & Trends
Nexalin Technology's Capital Expenditures history runs 1 years deep, the most recent figure standing at $49276.0 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 399.00 Mn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 166.00 Mn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 444.00 Mn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 177.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 64.90 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -85.46 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 76.60 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 86.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 90.20 Mn |
| 10 | Nexalin Technology | 7.82 Mn | 5.11 Mn | 13,133.00 | 49,276.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49,276.00 |
| Mar 31, 2026 | 49,276.00 |